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a b s t r a c t 
There is increasing evidence that coronavirus disease 2019 (COVID-19) is associated with a significant 
risk of venous thromboembolism. While information are mainly available for deep vein thrombosis of the 
lower limb and pulmonary embolism, scarce data exist regarding acute splanchnic vein thrombosis (SVT) 
in this setting. PubMed, EMBASE and Google Scholar English-language articles published up to 30 January 
2021 on SVT in COVID-19 were searched. Overall, 21 articles reporting equal number of patients were 
identified. 15 subjects presented with portal vein thrombosis, 11 with mesenteric vein thrombosis, four 
with splenic vein thrombosis, and two with Budd-Chiari syndrome. Male sex was prevalent (15 patients), 
and median age was 43 years (range 26–79 years). Three patients had a history of liver disease, while no 
subject had known myeloproliferative syndrome. Clinical presentation included mainly gastrointestinal 
symptoms. Anticoagulation was started in 16 patients. Three patients underwent bowel resection. Ten 
subjects developed gastric or bowel ischemia, seven of whom underwent bowel resection, and four died 
after SVT diagnosis. 
Although rare, SVT should be seen as a complication of COVID-19. Patients with severe gastrointestinal 
symptoms should be screened for SVT, as rapid recognition and correct management are essential to 
improve the outcome of these patients. 
© 2021 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. 































Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
s identified as responsible of coronavirus disease 2019 (COVID- 
9), a clinical condition ranging from mild symptoms, such as im- 
airment of the smell and taste, to the typical pulmonary man- 
festations including acute respiratory distress syndrome [1] . The 
irus may also directly damage the intestinal mucosa [2] , as gas- 
rointestinal symptoms have been widely reported [3 , 4] . Further- 
ore, increasing evidence showed that COVID-19 might be asso- 
iated with hemostasis impairment, thus predisposing patients to 
oth venous and arterial thromboembolism [5] . While the associ- 
tion between COVID-19 and deep vein thrombosis of the lower 
imb and pulmonary embolism has been extensively investigated, 
ess is known about thrombotic events in other districts, such as 
planchnic vein thrombosis (SVT). SVT is an uncommon manifes- ∗ Corresponding author at: Hepatology, Department for Visceral Surgery and 
edicine, Bern University Hospital, University of Bern, Switzerland. 
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atic review, Digestive and Liver Disease, https://doi.org/10.1016/j.dld.20ation of venous thromboembolism (VTE) that includes portal vein 
hrombosis (PVT), mesenteric vein thrombosis (MVT), and throm- 
osis of the liver veins or vena cava inferior (Budd-Chiari syn- 
rome, BCS). SVT is more often diagnosed in patients with cirrho- 
is or liver malignancy. Other predisposing factors, which are often 
bserved in patients with non-cirrhotic liver, are intra-abdominal 
urgery, infections and inflammatory diseases, as well as inherited 
r acquired thrombophilia [6] . 
Assuming that the splanchnic venous system could be also af- 
ected by the COVID-19-related coagulopathy, we conducted a sys- 
ematic review of current literature on SVT and COVID-19. 
. Methods 
We searched in PubMed, EMBASE and Google Scholar English- 
anguage articles published between November 2019 and 30th Jan- 
ary 2021 including the following MeSH terms “COVID-19 (and re- 
ated terms 2019 novel coronavirus, SARS-CoV-2 infection, 2019- 
CoV infection) and splanchnic vein thrombosis”, “COVID-19 and 
ortal vein thrombosis”, “COVID-19 and mesenteric vein thrombo- terologica Italiana S.r.l. This is an open access article under the CC BY license 
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is”, “COVID-19 and Budd-Chiari syndrome”, “COVID-19 and bowel 
schemia”. Case reports, case series, commentaries, letters to edi- 
ors, and review articles were considered. We evaluated indepen- 
ently title and abstract for inclusion, double-checking for dupli- 
ation and extracting the data using the text, tables, and figures 
f the original published articles. Cross-referencing yielded no ad- 
itional records and duplicate articles were assessed and subse- 
uently eliminated. All the demographic and clinical characteris- 
ics, clinical course and outcomes are reported using median and 
ncidence. 
. Results 
Overall, 641 articles were screened, 21 of which were selected 
ccording to the above mentioned criteria [7 –27] . The included ar- 
icles were all case reports (except for one case series [10] ), and 
ontained description of 21 cases. Overall, 15 patients presented 
ith PVT, 11 with MVT, 4 with splenic vein thrombosis, and 2 with 
CS. The clinical features, management and outcome are showed in 
ables 1 and 2 and summarized in Fig. 2 . 
.1. Comorbidities 
Male sex was prevalent (15 patients), and median age was 43 
ears (range 26–79 years). 
Comorbidities included cardiovascular risk factors like obesity 
3 patients), type 2 diabetes (2 patients), arterial hypertension and 
yperlipidemia (one patient each), as well as asthma (2 patients), 
arkinson disease and vascular dementia (one patient each). Three 
atients had a history of known liver disease (non-alcoholic steato- 
epatitis (NASH) plus hepatitis B virus (HBV) cirrhosis, chronic 
epatitis B, and alcohol-associated cirrhosis). Except for one pa- 
ient with operated craniopharyngioma, none of the patients had a 
istory of neoplasia or myeloproliferative neoplasms (MPN). In one 
ase, imaging tests performed at admission documented multifocal 
iver lesions consistent with hepatocellular carcinoma in the set- 
ing of newly discovered chronic hepatitis B, whereas no neoplas- 
ic thrombus was reported in the patient with known cirrhosis on 
ASH and HBV on the investigations performed. For ten patients, 
o comorbidities were reported. 
.2. Presentation 
Symptoms and/or signs of SVT were present at COVID-19 onset 
n ten cases, whereas in seven patients SVT represented a belated 
anifestation (range 5–21 days). For one subject, SVT was diag- 
osed as occasional finding with imaging performed in the setting 
f COVID-19. 
Clinical presentation included mainly gastrointestinal symp- 
oms, such as abdominal pain (16 patients), and vomiting (7 pa- 
ients). Jaundice and diarrhea were reported in one case each. 
ever was present for 7 patients, while dyspnea, cough and al- 
ered mental status were reported in 4 cases each. One patient had 
 large volume hematemesis following initiation of heparin for a 
ower extremity deep vein thrombosis during COVID-19. 
.3. Diagnosis of SVT and of COVID-19 
SVT was diagnosed in the outpatient setting in 17 cases. Al- 
ost all the diagnosis of SVT required a computed tomography 
CT) scan to be confirmed, except in one case (abdominal Doppler 
ltrasound, DUS). Eight patients displayed multivessel involvement, 
ncluding upper mesenteric artery for one patient. At the time of 
VT diagnosis, features of gastric or bowel ischemia were reported 
n ten cases. 2 Diagnostic tests for COVID-19 included real-time reverse tran- 
cription polymerase chain reaction (RT-PCR) on nasopharynx swab 
or 16 patients, confirming COVID-19 in eleven cases, and sero- 
ogical test in 3 cases, all of which were positive. For one sub- 
ect, SARS-CoV-2 infection was confirmed by immunohistochem- 
stry on a specimen of the resected small bowel, while for two 
atients the disease was suspected based on clinical features and 
ulmonary findings at imaging, despite a negative RT-PCR on na- 
opharynx swab. For 5 patients, the diagnostic test used was not 
eported by the authors. 
Diagnostic workup for inherited or acquired thrombophilia was 
eported in 11 cases, two of which had positive lupus anticoagulant 
LAC) (one at low titer), and one an established diagnosis of essen- 
ial thrombocythemia (ET). Further tests performed were reported 
s negative by the authors. 
.4. Treatment and outcomes 
Before SVT was diagnosed, three patients were taking antico- 
gulation therapy (one at therapeutic dose). After the diagnosis, 
n anticoagulation treatment was started in 16 cases, including 
nfractionated heparin (UFH) or low molecular weight heparin 
LMWH) (11 patients), and Apixaban (2 patients). In three case, 
he anticoagulant treatment introduced was not specified. Seven 
atients with radiological features of intestinal ischemia under- 
ent bowel resection, one of whom had also thrombolysis and 
hrombectomy in the context of upper mesenteric artery throm- 
osis. 
Outcome was available only for 14 patients, four of whom died. 
hese were 2 males and 2 females, aged 79, 62, 61, and 42, respec- 
ively. One subject had no known comorbidities, another one had 
nly diabetes reported, the third one had diabetes, obesity, arterial 
ypertension and cirrhosis, while the last one had extreme obesity 
nd a ventriculoperitoneal shunt due to a partially resected cran- 
opharyngioma. All these patients had multivessel involvement, in- 
luding upper mesenteric artery, as well as bowel ischemia com- 
licating SVT. 
Two subjects had clinical worsening following anticoagulant 
herapy (one due to subsequent bowel ischemia, and the other one 
ue to tight stenosis of mid-jejunum caused by congenital adhe- 
ion band). Both underwent bowel resection and were discharged 
hereafter. In one case, a 6-week follow-up imaging showed an es- 
ablished PVT with collateralization extending into the upper ab- 
omen. At last, two patients had gastrointestinal bleeding after an- 
icoagulant treatment introduction. 
. Discussion 
Venous thromboembolism is a common complication of inpa- 
ients with COVID-19, with a prevalence as high as 21% in a recent 
eta-analysis of over 8 thousand patients [28] . The mechanisms 
nderpinning the strong relationship between SARS-CoV-2 infec- 
ion and venous and arterial thromboembolism are not clear yet, 
nd likely include endothelial dysfunction, excessive inflammatory 
esponse, and hemodynamic components (stasis) [29 –33] . 
There is no specific data regarding SVT, but it can be hypothe- 
ized that the above-mentioned mechanisms in patients with pre- 
isposing conditions such as chronic liver disease or MPD can lead 
o a preferential splanchnic location of thrombosis ( Fig. 1 ). Inter- 
stingly, however, in a meta-analysis by Diaz et al. on histopatho- 
ogical reports from deceased COVID-19 patients undergoing au- 
opsy or liver biopsy, almost 30% of cases presented hepatic vascu- 
ar thrombosis in spite of a low prevalence of known chronic liver 
isease [34] . 
In the here reviewed cases, male gender was prevalent with a 
















































































therapy at the time 
of SVT diagnosis 
De Barry et al. [1] France 79, F Outpatient None Negative RT-PCR 
on nasopharynx 
swab. Suspicion of 
COVID-19 based on 
clinical features 
and pulmonary 
findings at imaging 
Symptoms/signs of 
SVT at COVID-19 
onset 




located in the 
epigastric area, 
associated with 
diarrhea during 8 
days 
Ignat et al. [2] France 28, F Outpatient None Not reported Symptoms/signs of 
SVT at COVID-19 
onset 
None Abdominal pain 
and vomiting with 
abdominal 
guarding at clinical 
examination 








swab. Diagnosis of 
SARS-CoV-2 
infection based on 





SVT at COVID-19 
onset 
None Abdominal pain 
and bilious 
vomiting during 3 











Not reported Not reported Not reported Not reported 












followed by mild 
abdominal pain 
with bloating and 
constipation, 
periumbilical 
tenderness, and no 
rebound reaction 
nor ascites at 
clinical 
examination 
Osofu et al. [6] US 55, M Outpatient Hyperlipidemia Not reported Occasional finding, 
no symptom/sign 
of SVT at diagnosis 
None Fever, shortness of 
breath, and altered 
mental status 
during 3 days 
Franco-Moreno 
et al. [7] 
Spain 27, M Outpatient None Negative RT-PCR 
on nasopharynx 
swab. Diagnosis of 
SARS-CoV-2 




21 days None Fever and dry 




Tenderness in the 
right upper 
quadrant at clinical 
examination 
Del Hoyo et al. [8] Spain 61, F Outpatient T2DM Positive RT-PCR on 
nasopharynx swab 
and serological test 
Symptoms/signs of 
SVT at COVID-19 
onset 
None Severe acute 
abdominal pain 
and vomiting 
Qing Pang et al. [9] Singapore 30, M Outpatient None Positive RT-PCR on 
nasopharynx swab 
Symptoms/signs of 
SVT at COVID-19 
onset 
None Colicky abdominal 
pain and vomiting 
during 2 days 
Low et al. [10] US 51, M Not reported Not reported Not reported Not reported Heparin (not 
specified) 
Large volume of 
hematemesis 
following initiation 














































































fatigue during 7 
days, followed by 
severe abdominal 
pain located in the 
right upper 
quadrant 
Lari et al. [12] Kuwait 38, M Outpatient None Positive RT-PCR on 
nasopharynx swab 
Symptoms/signs of 







shortness of breath 





out of proportion 
to the palpation at 
clinical 
examination 
Filho et al. [13] Brazil 33, M Outpatient Obesity Positive RT-PCR on 
nasopharynx swab 
11 days None Dry cough, fever, 
and fatigue during 
11 days, followed 
by severe low back 
pain radiating to 
the hypogastric 
region 
Thuluva et al. [14] Singapore 29, M Outpatient None Positive RT-PCR on 
nasopharynx swab 
Symptoms/signs of 
SVT at COVID-19 
onset 






Abeysekera et al. 
[15] 
UK 42, M Outpatient Chronic hepatitis B 
(undetectable viral 






swab. Diagnosis of 
SARS-CoV-2 
infection based on 
serological test 
14 days None Fever and cough 





Aleman et al. [16] Ecuador 44, M Outpatient None Positive RT-PCR on 
nasopharynx swab 
7 days None Severe 
abdominopelvic 
pain of progressive 
and insidious 




Nakamura et al. 
[17] 
Mexico 42, F Outpatient Extreme obesity, 
and ventriculoperi- 
toneal shunt due 





swab. Suspicion of 
COVID-19 based on 
clinical features 
and pulmonary 
findings at imaging 
Symptoms/signs of 
SVT at COVID-19 
onset 
None Colic abdominal 
pain associated 
with a difficulty 
with passing gases 
and a weeklong 
constipation 
Hambali et al. [18] Malaysia 55, M Outpatient Active smoking Positive RT-PCR on 
nasopharynx swab 
Symptoms/signs of 





swelling for 10 
days 
Alharthy et al. [19] Saudi Arabia 45, M Outpatient None Positive RT-PCR on 
nasopharynx swab 
Symptoms/signs of 
SVT at COVID-19 
onset 




Goodfellow et al. 
[20] 




Positive RT-PCR on 
nasopharynx swab 
5 days None Epigastric pain 
radiating through 
to the back with 
nausea 
Rozenshteyn et al. 
[21] 
US 50, M Outpatient Alcohol-associated 
cirrhosis 
Positive RT-PCR on 
nasopharynx swab 





















































































De Barry et al. [1] CT scan Right portal vein 
thrombosis 
originating from 
the distal part of 
the upper 
mesenteric vein 




thrombosis of the 
upper mesenteric 
and jejunal arteries 
Features of bowel 
ischemia of the 
cecum and small 
intestine, small 
amount of liquid 
in the peritoneal 
cavity 






Ignat et al. [2] CT scan Superior 
mesenteric vein 
and portal vein 
thrombosis 
None Signs of segmental 
portal 
hypertension with 
gastric varices and 
portal cavernoma 














Norsa et al. [3] CT scan Superior 
mesenteric vein 
thrombosis 
Inferior vena cava 
thrombosis 
High suspicion of 
small bowel 
ischemia 
Not reported Bowel resection Death 
Dane et al. [4] DUS Main portal vein 
thrombosis 
extending to the 
right and left 
portal veins 
Not reported Not reported Not reported Not reported Not reported 
La Mura et al. [5] CT scan Total occlusion of 
the left portal 
venous system and 
the secondary 
branches of the 
right portal vein 
None Large area of 
transient hepatic 
attenuation 







Factors II and VII 
were normal. 
Otherwise, the 










Osofu et al. [6] CT scan Thrombosis of the 
main right anterior 
and posterior 
divisions of the 








Proteins C and S 
were normal 
Apixaban 5 mg bid Discharge 
Franco-Moreno 
et al. [7] 
CT scan Thrombosis of the 
right branch of the 
portal vein 







Proteins C and S, 
Antithrombin and 








UI/kg bid, followed 
by acenocoumarin 
Discharge 
Del Hoyo et al. [8] CT scan Right hepatic vein 
thrombosis and 
complete 
thrombosis of the 
spleno-portal axis 
None Ileo-jejunal and 
right colon wall 







detectable at low 
titer, whereas 






















































































Table 2 ( continued ) 
Qing Pang et al. [9] CT scan Superior 
mesenteric vein 
thrombosis 
None Diffuse mural 










due to tight 
stenosis of mid 




excision and bowel 
resection. Patient 
discharged 
thereafter to a 
community 
isolation facility 
Low et al. [10] CT scan Non-occlusive 
thrombus in the 







portal venous gas 





According to the 
authors, the 
patient had 
resolution of the 
intramural gastric 
and portal venous 
gas, with no 
residual portal 
vein thrombosis at 
imaging one week 
later 









Lari et al. [12] CT scan Extensive 







High suspicion of 
ischemia of the 
mid-portion of the 
small bowel 
According to the 
authors, the 




were negative with 
low/clinically 
insignificant titers 






Still in ICU at the 
time of manuscript 
submission 
Filho et al. [13] CT scan Inferior mesenteric 
vein thrombosis 
None Infiltration of the 
adjacent adipose 
planes 
Not reported Enoxaparin 
(therapeutic dose), 
warfarin after 5 
days 
Discharged 
Thuluva et al. [14] CT scan Superior 
mesenteric vein 
thrombosis 














Not reported Low molecular 
weight heparin 
100 UI/kg bid 
Unknown. 
According to the 
authors, the 
patient showed an 
improvement of 
abdominal pain, 
and resumed a 
normal diet by day 
6 of hospitalization 













































































Table 2 ( continued ) 
Abeysekera et al. 
[15] 
Suspected at DUS, 
confirmed at CT 
scan 








According to the 
authors, the 













Apixaban 5 mg bid Unknown. 
According to the 
authors, an 
imaging 6 weeks 





extending into the 
upper abdomen, 
the patient being 
asymptomatic 
Aleman et al. [16] DUS and CT scan Superior 
mesenteric, 
splenic, and portal 
vein thrombosis 









Nakamura et al. 
[17] 
CT scan Portal vein and 
mesenteric veins 
thrombosis 
None Ileum, wall edema 
and perfusion 
alterations due to 
stress, absence of a 
defined transition 
zone, peritoneal fat 
stripes, and 
abdominopelvic 
collection in the 
mesentery 
Not reported Bowel resection Death 
Hambali et al. [18] CT scan Portal vein 
thrombosis 
None Multifocal liver 
lesions 
Not reported No anticoagulation 
therapy reported 
Discharge 






According to the 
authors, the 
patient was tested 









levels of proteins C 
and S, 
homocysteine, 










Goodfellow et al. 
[20] 
CT scan Superior 
mesenteric vein 
thrombosis 
None Diffuse infiltration 




thickening in the 
small bowel 
According to the 
authors, the 
patient was tested 














Rozenshteyn et al. 
[21] 
Suspected at DUS, 





the inferior vena 




None None Not reported Variceal band 






List of abbreviations CT computed tomography; DUS Doppler ultrasound; ECMO extracorporeal membrane oxygenation; SVT splanchnic vein thrombosis 
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Fig. 1. Hypothesis of pathological mechanisms of SARS-CoV-2 infection and splanchnic vein thrombosis. List of abbreviations ACE2 Angiotensin-converting enzyme II; NETs 












































ge of patients developing venous thromboembolic events other 
han SVT during COVID-19 ranges between 60 and 70 years [35 , 36] .
oncerning SVT in other clinical scenarios, the mean age of pa- 
ients is estimated between 50 and 60 years in case of PVT [37] ,
nd between 70 and 79 years for MVT [38] . Therefore, the data 
eported herein seem to suggest an uncommonly young age in pa- 
ients developing SVT and concomitant COVID-19. 
Clinical presentation of SVT was often unspecific, especially in a 
ontext of multiorgan involvement and failure, making its prompt 
dentification challenging. Typical presentation for patients with- 
ut COVID-19 includes abdominal pain, reported in almost half of 
ases, gastrointestinal bleeding and ascites [39] . Abdominal pain 
as also the main reported symptom in the reported series, fol- 
owed by vomiting and fever. 
As for the known risk factors for SVT, only two patients had 
nown liver cirrhosis. In one case, imaging tests performed at ad- 
ission documented multifocal liver lesions consistent with hep- 
tocellular carcinoma in the setting of newly discovered chronic 
epatitis B. Advanced liver disease is itself a risk factor for SVT. 
efining a clear etiological role of SARS-CoV-2 different in this 
opulation from SVT in non-cirrhotic patients remains unclear. 
owever, it is likely that SARS-CoV-2 represents a further trigger 
n this context as well. Indeed, a worsening effect of COVID-19 
n the prognosis of patients with cirrhosis is well established and 8 rogression of PVT in patients despite prophylactic therapy with 
MWH has been reported [40] . 
Interestingly, in one case COVID-19 diagnosis was possible with 
NAs in situ hybridization technique applied to the resected small 
owel, suggesting that local inflammation due to SARS-CoV-2 in- 
ection might be a major trigger in the development of SVT for 
hese patients. 
The diagnostic workup for inherited or acquired thrombophilia 
ed in one case to a new diagnosis of ET, while positive LACs were 
ound in two patients. In non-cirrhotic SVT, the mean prevalence 
f JAK2 V617F mutation ranges between 41.1 and 27.7%, while the 
ean prevalence of MPN is estimated at 40.9% and 31.5% for BCS 
nd PVT, respectively. Additionally, for almost 20% of the subjects 
ith SVT, JAK2 V617F screening identified MPN in patients other- 
ise with no typical feature of MPN [41] . 
With regard to LAC positivity, recent observations have sug- 
ested that single LAC positivity is a common finding during 
he acute phase of SARS-CoV-2 infection, without a clear causal 
elationship with thrombotic events. Conversely, other high-risk 
hrombophilia conditions, such as triple antiphospholipid antibod- 
es positivity or high anticardiolipin/antibeta2-glycoprotein I an- 
ibodies, have rarely been described in this setting [42] . Impor- 
antly, since these findings have often been transient, unconfirmed 
t later measurements and not consistently associated with throm- 
G. Buso, C. Becchetti and A. Berzigotti Digestive and Liver Disease xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: YDLD [m5G; June 10, 2021;4:48 ] 
Fig. 2. General and clinical features, management and outcomes in the SVT patients presented in this systematic review . List of abbreviations BCS Budd-Chiari syndrome; 
LMWH low molecular weight heparin; MVT mesenteric vein thrombosis; PVT portal vein thrombosis; SVT splanchnic vein thrombosis; HCC hepatocellular carcinoma, HBV 































































otic events, they may not be an adequate screening tool for ac- 
uired thrombophilia in the acute phase of the disease [43] . 
In the here reviewed cases, SVT was assessed using DUS imag- 
ng only for one patient, whereas in the rest of the cases CT scans 
uled out the diagnosis. One patient, a young woman who was 
ater on diagnosed of ET, showed signs of cavernous transformation 
f the portal vein and large porto-systemic collaterals, suggesting 
he presence of an acute on chronic thrombosis. DUS is a validated 
echnique in detecting SVT with an accuracy up to 90% for diag- 
osing PVT, cavernous transformation of the PV and BCS [44] , al- 
hough the sensitivity of DUS is lower for mesenteric and splenic 
eins [45] . CT scan or similar cross-sectional imaging should be al- 
ays considered as diagnostic tool, which may also be used to in- 
estigate the presence of signs of bowel ischemia [46] and assess 
he extent of involvement of all the vessels of the PV system, since 
nvolvement of more than one vessel indicates a worse prognosis 
47 , 48] . In 8 of the SVT here reviewed cases, thrombosis involved
ore than one vessel. 
Of note, three patients were on anticoagulation at SVT diagno- 
is, of whom one at therapeutic dose for concomitant deep venous 
hrombosis (unclear if in the outpatient or inpatient setting). One 
atient was receiving LMWHs at standard prophylactic dose in a 
OVID-19 Unit, and another one in the outpatient setting. In the 
nly reported case of SVT occurring during ICU stay, the presence 
f pharmacological prophylaxis of thrombosis was not reported. 
revious research suggested that the incidence of thrombotic com- 
lications in ICU patients with COVID-19 infections is remarkably 
igh despite anticoagulant therapy at standard prophylactic dose 
49] . Notwithstanding this, recent evidence on patients admitted to 
he ICU with COVID-19 showed that intermediate-dose prophylac- 
ic anticoagulation did not result in a significant difference in the 
rimary outcome of a composite of adjudicated venous or arterial 
hrombosis, treatment with extracorporeal membrane oxygenation, 9 r mortality within 30 days [50] . This might also hold true as for 
VT. Ongoing trials should clarify the role of different prophylaxis 
trategies in the outpatient setting, including LMWHs at standard 
rophylactic dose, DOACs at both low and high intensity, aspirin, 
nd sulodexide [51] . 
The goal of treatment of acute SVT is to achieve the patency 
f the vein, thus preventing bowel infarction, liver injury, and late 
omplications of portal hypertension. The timing for starting an 
nticoagulant therapy is crucial in order to avoid potentially life- 
hreatening gastrointestinal bleeding. All but five patients included 
n the present systematic review received anticoagulant therapy. 
owever, four patients who underwent urgent intestinal resection 
ave died, thus supporting the importance of immediate surgical 
valuation in subjects with severe abdominal clinical presentation 
e.g. bowel infarction at imaging, peritonitis, septic shock) even be- 
ore considering the anticoagulant treatment. Preventive evaluation 
f signs of portal hypertension including gastroesophageal varices 
hould be evaluated in a case-by-case basis in this context [46] . 
Evidence on which anticoagulant therapy should be used in pa- 
ients with SVT is limited and choice is based mostly on clini- 
al experience. UFH, LMWH and vitamin K antagonists are com- 
only used. The use of direct oral anticoagulants (DOACs) still re- 
ains off-label in most countries for SVT [46] . Potential malab- 
orption in case of intestinal ischemia should be always consid- 
red as a potential risk of lack of efficacy for oral therapy. Cur- 
ent recommendations for in-hospital patients with COVID-19 re- 
uiring anticoagulation suggest LMWH as first-line treatment [52] , 
mphasizing its higher stability compared with UFH, particularly 
uring the cytokine storm phase, and its reduced risk of interac- 
ion with antiviral drugs compared with DOACs. Indeed, antiviral 
herapy for COVID-19 has been reported to dramatically increase 
OACs plasma levels [53] . Accordingly, the use of LMWH may con- 
titute the most effective and safe strategy also for patients with 
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VT during COVID-19. Future research is needed to clarify these 
spects. 
Limitations of the present systematic review include the small 
umber of cases reported, and reporting bias (likely reporting of 
he most severe cases). The conclusions of the present study rely 
n the quality and accuracy of the reports included in the analysis. 
. Conclusions 
SVT has been reported in 21 COVID-19 cases so far, and as such 
t can be considered as an uncommon manifestation of SARS-CoV- 
 infection. However, SVT is often fatal, thereby requiring prompt 
ecognition and treatment. Young patients and subjects without 
nown comorbidities may be at risk of developing this complica- 
ion. A high level of warning should be raised in presence of SVT- 
ompatible symptoms in the setting of COVID-19. 
Particular attention should be given to screening of inherited 
r acquired thrombophilia, bearing in mind the correct timing for 
esting. DUS and cross-sectional imaging remains essential for di- 
gnosis and mapping of thrombosis extent in the portal venous 
ystem. Careful monitoring of potential signs of bowel ischemia 
hould be performed, in order to provide appropriate treatment at 
arly stages. 
Future perspectives might embrace long-term follow-up of pa- 
ients with SVT and COVID-19, aiming to evaluate its natural his- 
ory, including development of late portal hypertension, specific 
istological alterations of the liver parenchyma, and vessels re- 
analization rates. In this sense, an international registry could 
e an extremely useful tool to document and group such spo- 
adic cases, and follow-up the clinical evolution of these patients 
ver time. Identifying the pathophysiological mechanisms underly- 
ng the relationship between SARS-CoV-2 infection and SVT may 
lso be of great interest. 
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